Advances in Pharmacological Properties, Molecular Mechanisms, and Bioavailability Strategies of Chlorogenic Acid in Cardiovascular Diseases Therapy.

IF 4.8 3区医学 Q2 CHEMISTRY, MEDICINAL

Pharmaceuticals Pub Date : 2025-09-11 DOI:10.3390/ph18091357

Kai Huang, Duosu Zhang, Ruting Wang, Jiahao Duan, Long Hu, Fan Huang, Wei Liu, Jia Gu, Songlin Li, Chun Yang, Ling Yang

{"title":"Advances in Pharmacological Properties, Molecular Mechanisms, and Bioavailability Strategies of Chlorogenic Acid in Cardiovascular Diseases Therapy.","authors":"Kai Huang, Duosu Zhang, Ruting Wang, Jiahao Duan, Long Hu, Fan Huang, Wei Liu, Jia Gu, Songlin Li, Chun Yang, Ling Yang","doi":"10.3390/ph18091357","DOIUrl":null,"url":null,"abstract":"Cardiovascular diseases (CVDs), a group of global diseases, are characterized by high morbidity and mortality, imposing a significant burden on clinical practice. Chlorogenic acid (CGA), a natural compound composed of caffeic acid and quinic acid, is widely found in and extracted from plants such as Lonicera japonica (honeysuckle), Eucommia ulmoides (hardy rubber tree), tea leaves, and coffee beans. In recent years, increasing attention has been directed towards the pharmacological mechanisms of CGA in the treatment of CVDs. This review comprehensively summarizes the current knowledge on the preparation, metabolic pathways, pharmacological effects, and safety profile of CGA. Furthermore, it systematically analyzes the biological effects and molecular targets of CGA in the cardiovascular therapy and highlights strategies to enhance its bioavailability. These insights aim to provide a scientific basis for future basic research and clinical applications.","PeriodicalId":20198,"journal":{"name":"Pharmaceuticals","volume":"18 9","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472252/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ph18091357","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Cardiovascular diseases (CVDs), a group of global diseases, are characterized by high morbidity and mortality, imposing a significant burden on clinical practice. Chlorogenic acid (CGA), a natural compound composed of caffeic acid and quinic acid, is widely found in and extracted from plants such as Lonicera japonica (honeysuckle), Eucommia ulmoides (hardy rubber tree), tea leaves, and coffee beans. In recent years, increasing attention has been directed towards the pharmacological mechanisms of CGA in the treatment of CVDs. This review comprehensively summarizes the current knowledge on the preparation, metabolic pathways, pharmacological effects, and safety profile of CGA. Furthermore, it systematically analyzes the biological effects and molecular targets of CGA in the cardiovascular therapy and highlights strategies to enhance its bioavailability. These insights aim to provide a scientific basis for future basic research and clinical applications.

查看原文本刊更多论文

绿原酸在心血管疾病治疗中的药理特性、分子机制及生物利用度策略研究进展

心血管疾病（cvd）是一组全球性疾病，其特点是发病率和死亡率高，给临床实践带来了重大负担。绿原酸（CGA）是一种由咖啡酸和奎宁酸组成的天然化合物，广泛存在于忍冬、杜仲、茶叶和咖啡豆等植物中，并从这些植物中提取。近年来，人们越来越关注CGA治疗心血管疾病的药理机制。本文对CGA的制备、代谢途径、药理作用和安全性等方面的研究进展进行了综述。系统分析了CGA在心血管治疗中的生物学效应和分子靶点，并提出了提高其生物利用度的策略。这些见解旨在为未来的基础研究和临床应用提供科学依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceuticals Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

6.10

自引率

4.30%

发文量

1332

审稿时长

6 weeks

期刊介绍： Pharmaceuticals (ISSN 1424-8247) is an international scientific journal of medicinal chemistry and related drug sciences.Our aim is to publish updated reviews as well as research articles with comprehensive theoretical and experimental details. Short communications are also accepted; therefore, there is no restriction on the maximum length of the papers.